+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

The Pharmacology of Next Generation Therapeutics

Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation

$5,000 Challenge Award for Trainees

The PhRMA Foundation and ASPET’s Journal of Pharmacology and Experimental Therapeutics (JPET) are partnering on a Challenge Award competition that will award trainees for outstanding papers addressing the pharmacology of next generation therapeutics.

The PhRMA Foundation will provide the Challenge Award — a prize of $5,000 — to the first author of up to five winning papers, and JPET will publish these accepted manuscripts as part of a special collection. Additionally, the Foundation will pay JPET’s open-access publishing fee for each winning paper.

Deadline: July 1, 2025

Scope of the Call

JPET is planning a new special collection titled “Pharmacology of Next Generation Therapeutics.”

In recent years, there has been an explosion in FDA-approved therapeutic modalities to treat myriad diseases, including cell therapies, gene therapy, siRNA, mRNA, and T-cell engagers, among others. With novel modalities come new pharmacologic mechanisms of action, PK/PD relationships, and safety considerations.

This special collection will broadly cover original research and minireviews on the pharmacology of novel modalities, both those that have entered the clinic in recent years and those that are still investigational. Manuscripts are encouraged to describe characterization of novel therapeutic classes, evaluation of new modalities in animal models, and characterization of the PK/PD relationship for these therapeutics. Original research articles or minireviews will be considered.

AI Based Application Success Predictor

1. High-Risk & High-Reward Innovation 🚀

Funders—including ASPET/PhRMA Foundation Challenge Awards—are drawn to truly novel concepts like gene therapies, cell-engaging biologics, or next-gen delivery systems
Grants that explicitly challenge existing paradigms or pioneer emerging modalities tend to rank highly.

2. Effective Use of Promotional Language

Studies across agencies (NIH, NSF, Novo Nordisk Foundation) show that proposals using confident, clear, “promotional” wording about innovation or impact can double funding odds .
Tip: Assert the transformative potential of your therapeutic up front.

3. Strong Investigator Credentials & Track Record

Competitiveness increases with:

Relevant expertise (PK/PD, biologics, advanced modalities)

Publications or preliminary data in next-gen drug fields

Evidence of leadership in multidisciplinary research .

4. Detailed PK/PD Strategy and Methodology

Next-gen therapeutics have unique pharmacokinetic/dynamic profiles. Reviewers expect:

Rigorous PK/PD modeling

Clear validation for assays or signaling pathways

Preclinical data in relevant models (animal or organoid)
Include quantitative go/no-go milestones tied to pooling strategies or dosing outcomes.

5. Structured Milestones & Feasibility

Top-scoring applications use detailed Gantt charts, with milestones and quantitative success criteria after each phase .
Demonstrate feasibility with realistic timelines and clear decision points.

6. Multidisciplinary & Translational Team

Grants focused on next-gen therapeutics succeed with teams spanning:

PK/PD scientists, delivery system engineers, clinicians

Project management and regulatory or manufacturing expertise .
Clear team structure and roles (especially in NIH NCATS and translational calls) are essential.

7. Clear Path to Translation or Impact

Whether aiming for publication, Phase I trials, or venture-readiness, you must outline:

How your data enables follow-on funding

Potential for regulatory or clinical advancement

Transparency around IP and commercialization, especially for private funders

8. Budget Precision & Justification

Seed or Challenge grants typically limit funding (~$5K–$150K). Your proposal should:

Include only direct research costs

Align resource allocation tightly with milestones and deliverables.

🧩 Summary Table

Predictor	Why It Matters
Bold, innovative concept	Core to next-gen therapeutic funding
Promotional language	Scientifically shown to increase funding odds
Strong track record	Signals capability to execute
Robust PK/PD plan & assays	Reflects rigor and feasibility
Milestone-based Gantt timeline	Demonstrates planning and accountability
Multidisciplinary team	Ensures translational reach
Translational pathway clarity	Shows future potential
Budget alignment	Fits funder expectations

✅ Tips to Strengthen Your Application

Open with a strong “why now” statement, emphasizing novelty and impact.

Use clear, assertive language—labels like “transformative,” “paradigm-shifting.”

Map out quantitative go/no-go criteria in the aims and timeline.

Explain PK/PD innovation and why your model is uniquely suited to the modality.

List each team member and their role, highlighting cross-disciplinary strength.

Describe the path from results to next steps—future trials, follow-up grants, regulatory.

Budget tightly, focusing on direct costs aligned with milestones.

Specialties

Pharmacology

Eligibility Requirements

First authors must be graduate students, postdoctoral fellows, or clinical residents (e.g., interns, residents, or fellows in medicine or pharmacy). All award money will be distributed to the first author only.
Papers must be submitted by July 1, 2025.
Authors must indicate in their cover letter that the paper is for the PhRMA Foundation Challenge Award competition.
Employees of pharmaceutical companies are allowed to compete but are not eligible to receive award money due to restrictions on provision of financial awards by the Foundation.

Sponsor Details

Sponsor Institute/Organizations: Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation

Sponsor Type: Corporate/Non-Profit

Address: 670 Maine Avenue SW, Suite 1000 Washington DC, 20024-3556 (202) 572-7756

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity